The Medicare GLP-1 Bridge Program may make taking a GLP-1 medication for weight loss a reality for you. Glucagon-like peptide-1 (GLP-1) use has skyrocketed in the U.S. since the FDA approved the first version for weight loss, Wegovy, in 2021. Scientists originally developed them to help regulate blood sugar in people with type 2 diabetes, but soon found they helped people lose significant weight, which in turn can help manage other conditions, such as cardiovascular disease. Today, there are 11 GLP-1 medications on the market, with an estimated 11% of U.S. adults taking one.
"It's a way for people who otherwise would not have access to them through their Medicare Part D plan to get these medications," says Lauren Oshman, MD, MPH, a family medicine professor and obesity specialist at the University of Michigan Medical School. "It's a temporary program, but it's an important opportunity for people who meet the criteria."
Your eligibility depends on a few factors, such as body mass index (BMI), certain health conditions, and whether Medicare Part D already covers a GLP-1 drug for you. Here's a breakdown of the program, and how you might qualify.
What Is the GLP-1 Bridge Program?
The Medicare GLP-1 Bridge is a program from the Centers for Medicare and Medicaid Services (CMS) that began July 1, 2026, and is scheduled to end on December 31, 2027. It gives certain people on Medicare access to select GLP-1 medications for a flat $50 monthly copay, regardless of income.
Why Was the Medicare GLP-1 Bridge Created?
Medicare has not historically covered drugs prescribed only for weight loss. When Medicare Part D began, there were few effective drugs for obesity. Today, the healthcare system has begun to view obesity — and its approach to treatment for it — differently, and newer GLP-1 drugs can help people lose significant weight and improve some health problems linked to obesity.
"The policy has not kept up with the science," Oshman says. "Now we know that obesity is a chronic disease. So along with this were some changes in the American Medical Association making a statement that obesity is a medical problem, not just an aesthetic problem."
CMS created the Bridge Program to improve access to these drugs and study how wider coverage might affect Medicare costs and health.
How Is This Different From the BALANCE Model?
While the GLP-1 Bridge Program is temporary, the BALANCE Model is Medicare's longer-term proposal for covering obesity medications. Many details are still undecided, including who would qualify and what the coverage rules would be. CMS says information from the Bridge Program may help shape BALANCE or another permanent program.
"The idea of the BALANCE model is essentially a way forward to have Medicare Part D cover medicines for the diagnosis of obesity," Oshman says. "But the finer questions, such as whether it will cover the same list of patients in BRIDGE, if there is going to be a different set of requirements, if there will be step therapy, or if you'll be required to be on a specific dietary plan — that's what is unknown to us."
Who Is Eligible for GLP-1 Bridge?
In order to qualify for the Bridge Program, you must be enrolled in Medicare Part D and meet certain health requirements related to obesity. You also cannot already qualify for GLP-1 coverage through Part D for another approved condition.
Your doctor must decide that a GLP-1 drug is appropriate as part of a complete weight management plan.
The four criteria for qualifying are as follows (you must meet all four):
- You have Medicare Part D drug coverage. If you're not sure what type of plan you have, call 800-MEDICARE (800-633-4227).
- You're not eligible to get your GLP-1 through your current Medicare plan. If you've already qualified for GLP-1 coverage under Medicare, you can't start coverage with Bridge.
- You don't have certain health conditions. These include type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease.
- You're at least 18 years old, AND meet BMI requirements. (See below.)
What BMI do you need to qualify?
Typically, a BMI above 35 qualifies you, even if you don't have other health conditions. But you may qualify with a lower BMI if you meet other criteria, too. These are the BMI qualification categories:
- 35 or higher, with no other health condition
- 30 or higher plus certain types of heart failure, or uncontrolled high blood pressure, or chronic kidney disease
- 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or peripheral artery disease
Does obesity need to be your primary diagnosis?
Usually, yes. The Bridge Program is for people seeking treatment for obesity and weight management. It is not meant for people who already qualify for GLP-1 coverage through Part D because of another medical condition. Your doctor will document why they're prescribing a GLP-1 for you.
What other health conditions can help you qualify?
If your BMI is below 35, certain health conditions may help you qualify. These include:
- Peripheral artery disease with symptoms
- Prediabetes
- Previous heart attack
- Previous stroke
- Heart failure with preserved ejection fraction
- Uncontrolled high blood pressure
- Stage 3a or higher chronic kidney disease
Does sleep apnea qualify you for the Medicare GLP-1 Bridge?
No. Since Medicare already covers certain GLP-1 drugs through Part D for people with obesity and moderate to severe obstructive sleep apnea, a sleep apnea diagnosis will disqualify you from using the Bridge Program.
The same general rule may apply if you already qualify for Part D coverage because you have type 2 diabetes, heart disease, or metabolic dysfunction-associated steatohepatitis (MASH). In those cases, your doctor and Part D plan will decide whether the drug is covered through your regular Medicare benefit.
Can you use the Medicare GLP-1 Bridge if you're already taking a GLP-1?
If you pay for the drug yourself or get it outside Medicare Part D, you may still qualify. But CMS generally excludes you if you previously had GLP-1 coverage through Part D. Oshman says CMS reviews prescription history during the approval process.
Who May Not Be Eligible?
You may not qualify for the Medicare Bridge Program if:
- You do not have Medicare Part D.
- You have type 2 diabetes and qualify for GLP-1 coverage through Part D.
- You have moderate to severe obstructive sleep apnea and qualify for coverage through Part D.
- You have MASH and qualify for coverage through Part D.
- Medicare Part D previously covered your GLP-1 drug.
- You do not meet the BMI and health condition requirements.
- You're under 18 years old.
Can you lose eligibility after starting a GLP-1?
If you lose or change your Medicare Part D coverage, you'll no longer qualify for the Bridge Program. Also, if you develop a health condition that qualifies you for a GLP-1 under Medicare Part D, you'll no longer be eligible for the Bridge Program coverage.
Oshman says CMS guidelines require doctors to use your BMI and qualifying health conditions from when you started treatment, not after you lose weight. For example, if your BMI was 37 when you started, you may remain eligible even if your BMI later drops below 35. Since taking the medication is key for helping control your BMI, a changing BMI isn't grounds for losing eligibility.
"If you stop using the treatment that's been effective for you, we know that you will regain weight," says Oshman.
Which GLP-1 Medications Are Covered by the Medicare Bridge?
The program covers:
- Wegovy, including shot and tablet forms
- Zepbound KwikPen
- Foundayo tablets
The program does not cover other types of Zepbound such as single-dose pens and vials.
How Much Do GLP-1 Drugs Cost Through the Medicare Bridge?
If you're eligible, you'll pay $50 a month for covered medications. The amount does not change based on your income or where you are in your Part D benefit year.
Are there any other out-of-pocket costs?
Because the $50 payment is separate from Part D, it doesn't count toward your Part D deductible or yearly out-of-pocket limit. Bridge prescriptions also are not included in the Medicare Prescription Payment Plan.
How To Enroll in the Medicare GLP-1 Bridge Program
There is no separate application for the Bridge Program.
"It's really just a process on the back end," says Oshman. "As a physician, when I send it to the pharmacy, it just goes to your pharmacy benefit manager, and they manage your prior authorization and the criteria, or they may request documents from your doctor before authorizing it."
Here is how the process usually works:
- Confirm that you have Medicare Part D.
- Make an appointment with your doctor to discuss obesity treatment and whether a GLP-1 drug is right for you.
- Your doctor reviews your BMI, medical history, and qualifying health conditions.
- If you qualify, your doctor prescribes a covered GLP-1 drug.
- Your doctor submits the prescription through the Medicare GLP-1 Bridge authorization system.
- The pharmacy receives approval and fills the prescription through the Bridge Program.
- You pay the $50 monthly copay.
Oshman recommends making an appointment with your doctor instead of sending a message through a patient portal. A full visit gives you and your doctor time to discuss how the medication fits into your overall treatment plan and potential side effects such as nausea, constipation, and dizziness.
"These aren't medicines we want to prescribe without a comprehensive lifestyle change," says Oshman. "We want to meet with you to talk about all the things you can do to support your health goals — and schedule follow-up visits, just like you would for any other chronic disease. So be patient, talk to your doctor, and come up with a plan that will work for you."
What Should You Do if Your Request Is Denied?
If your request is denied, you and your doctor will receive a notice. Your doctor can review the reason and, if needed, send more information or ask for another review.
Oshman says that if a denial seems to be a mistake, the doctor can submit the records again for review.
What Could Happen After the Bridge Period Ends?
CMS says it will use information from the program to help guide future decisions about coverage for obesity drugs. But once the program ends on December 31, 2027, the $50 copay coverage will expire.
Oshman is hopeful that Medicare will keep looking for ways to cover these drugs while negotiating lower prices.
"My sincere hope is that all medicines that are appropriate for obesity treatment will be covered and that there will be increased coverage for what we know works, which is lifestyle changes and physical activity, because that's so important to go along with for patients as they're losing weight," says Oshman.
Where to Find More Information on the GLP-1 Bridge Program
For the latest information, visit Medicare's GLP-1 Bridge resources or call 800-MEDICARE. Your primary care doctor, endocrinologist, cardiologist, or obesity medicine specialist can also help you find out whether you qualify and guide you through the prescription process.
